Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Commercial services symbols : LLY save search
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
Published: 2024-03-12 (Crawled : 12:00) - globenewswire.com
PFE | News 4 | $26.32 0.23% 0.15% 88K
|
Health Technology
|
| O: -0.21%
H: 0.11%
C: -1.06%
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: 0.9%
H: 2.03%
C: 1.89%
VERU | $1.275 0.39% 0.0% 2.6M
|
Health Technology
|
| O: -0.53%
H: 2.22%
C: -3.59%
ALT | $7.57 1.34% 1.19% 3.9K
|
Commercial Services
|
| O: 0.3%
H: 11.41%
C: 9.8%
medical program
Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - MediciNova, Eli Lilly and Company, AstraZeneca, Madrigal Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Pfizer
Published: 2024-01-22 (Crawled : 22:00) - prnewswire.com
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: -0.51%
H: 0.37%
C: 0.32%
MDGL | $218.38 2.29% 2.15% 190
|
Health Technology
|
| O: 1.29%
H: 0.35%
C: -3.04%
HEPA | $1.49 5.67% 4.08% 4
|
Health Technology
|
| O: -0.48%
H: 7.69%
C: 1.44%
ALT | $7.57 1.34% 1.19% 3.9K
|
Commercial Services
|
| O: -0.8%
H: 6.02%
C: 0.6%
ALNY | $146.07 0.19% 0.18% 540K
|
Health Technology
|
| O: 0.46%
H: 3.04%
C: 2.67%
ETNB | $8.92 -4.19% -4.37% 540K
|
Health Technology
|
| O: 1.19%
H: 0.63%
C: -0.72%
liver disease companies key growth market
ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
Published: 2023-10-03 (Crawled : 10:00) - globenewswire.com
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
ALXO M | $15.5 8.92% 8.19% 440K
|
Commercial Services
|
| O: 68.19%
H: 2.84%
C: -7.17%
aspen-06 positive cancer treatment trial results
Diabetic Peripheral Neuropathy Market Growing at a CAGR of ~6% by 2032 | DelveInsight
Published: 2023-07-20 (Crawled : 21:00) - prnewswire.com
BMEA | $10.98 1.39% 1.28% 530K
|
Professional, Scientific, and T...
|
| O: 0.71%
H: 3.64%
C: 0.61%
NVO | News | $128.64 2.7% -1.37% 60K
|
Health Technology
|
| O: -0.16%
H: 1.18%
C: 0.88%
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: 0.34%
H: 0.35%
C: -0.72%
VRTX | $404.91 1.25% 1.43% 730K
|
Health Technology
|
| O: 0.86%
H: 0.57%
C: -0.68%
APLT | $4.46 1.13% 1.01% 340K
|
Health Technology
|
| O: 1.46%
H: 6.12%
C: 2.88%
ALT | $7.57 1.34% 1.19% 3.9K
|
Commercial Services
|
| O: 1.57%
H: 0.0%
C: -2.79%
growing market diabetic
Nonalcoholic Steatohepatitis Market Evolving at a Rapid Pace, Predicts DelveInsight | Key Companies Active in the Domain - Madrigal, Intercept, AstraZeneca, Gilead, Pfizer, Alnylam, Eli Lilly and Company, Novo Nordisk
Published: 2023-04-24 (Crawled : 15:00) - prnewswire.com
NVO | News | $128.64 2.7% -1.37% 60K
|
Health Technology
|
| O: -1.02%
H: 0.31%
C: -0.24%
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: 0.0%
H: 0.47%
C: -0.49%
VKTX | $64.93 1.69% 1.75% 1.9M
|
Health Technology
|
| O: 0.99%
H: 2.87%
C: -0.42%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -0.22%
H: 0.0%
C: 0.0%
MTCR | $0.5814 -5.14% 84K
|
Health Technology
|
| O: 0.63%
H: 1.35%
C: 0.45%
MDGL | $218.38 2.29% 2.15% 190
|
Health Technology
|
| O: -0.33%
H: 1.28%
C: 1.12%
LPCN | $4.8 -5.33% -3.89% 0
|
Health Technology
|
| O: -2.31%
H: 7.94%
C: 1.01%
IONS | $41.84 1.88% 1.86% 260
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: -3.64%
HEPA | $1.49 5.67% 4.08% 4
|
Health Technology
|
| O: 0.04%
H: 1.48%
C: -3.31%
GALT | $3.38 10.46% 9.06% 240K
|
Health Technology
|
| O: 0.0%
H: 1.04%
C: -4.17%
CWBR | $0.9004 0.01% -11.88% 0
|
Health Technology
|
| O: -3.68%
H: 1.1%
C: -1.63%
ALT | $7.57 1.34% 1.19% 3.9K
|
Commercial Services
|
| O: -0.69%
H: 0.87%
C: -4.0%
ALNY | $146.07 0.19% 0.18% 540K
|
Health Technology
|
| O: -0.08%
H: 0.18%
C: -2.07%
ETNB | $8.92 -4.19% -4.37% 540K
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: -5.88%
companies active rapid market
Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements Exicure, Inc. an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting r...
Published: 2022-12-14 (Crawled : 12:00) - biospace.com/
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: 0.1%
H: 2.9%
C: 1.25%
XCUR 4 | $0.5403 0.11% -3.7% 5.5K
|
Commercial Services
|
| O: 0.0%
H: 11.14%
C: 0.79%
collaboration
ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer
Published: 2022-08-11 (Crawled : 16:00) - biospace.com/
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: -1.18%
H: 1.46%
C: 0.05%
ALXO M | $15.5 8.92% 8.19% 440K
|
Commercial Services
|
| O: 2.97%
H: 6.15%
C: -1.44%
trial cancer phase 2
Metastatic Castration-Sensitive Prostate Cancer Market to Reach Upto USD 5.5 billion by 2032 | DelveInsight
Published: 2022-06-20 (Crawled : 16:00) - prnewswire.com
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
| Email alert
Add to watchlist
XCUR 4 | $0.5403 0.11% -3.7% 5.5K
|
Commercial Services
| Email alert
Add to watchlist
ADAP | $1.14 12.87% 9.82% 1.1M
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
| Email alert
Add to watchlist
EVLO | $0.3165 -87.39% 710K
|
Health Technology
| Email alert
Add to watchlist
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
| Email alert
Add to watchlist
cancer market prostate cancer
ALX Oncology Announces Evorpacept Clinical Program Updates
Published: 2022-06-03 (Crawled : 12:00) - biospace.com/
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: -2.25%
H: 0.0%
C: 0.0%
ALXO M | $15.5 8.92% 8.19% 440K
|
Commercial Services
|
| O: 1.49%
H: 3.07%
C: 1.6%
program
Global Clinical Trials Market Research Report to 2026 - Featuring Accell Clinical Research, Clinipace and Icon PLC Among Others
Published: 2022-04-05 (Crawled : 13:00) - prnewswire.com
TMO | News | $574.59 4.78% 3.34% 2.2M
|
Health Technology
|
| O: -0.89%
H: 1.51%
C: -0.1%
NVO | News | $128.64 2.7% -1.37% 60K
|
Health Technology
|
| O: 0.57%
H: 1.02%
C: 0.31%
IQV | $238.62 3.15% 0.0% 7
|
Health Services
|
| O: -0.39%
H: 1.68%
C: 0.34%
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: 0.1%
H: 1.41%
C: 0.26%
CRL | News | $240.13 3.26% 0.78% 540K
|
Commercial Services
|
| O: 0.35%
H: 1.06%
C: 0.14%
SYNH | $42.98 0.0% 7.4M
|
Health Services
|
| O: -0.06%
H: 0.4%
C: -0.82%
ICLR | News | $306.45 2.86% 2.68% 5
|
Health Technology
|
| O: 0.07%
H: 0.52%
C: -0.43%
trials research report market
ALX Oncology Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept for the Treatment of Patients with Advanced Gastric or Gastroesophageal Junction CancerPhase 2/3 study initiated in collaboration with Eli Lilly and Company
Published: 2022-03-02 (Crawled : 18:00) - biospace.com/
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: 0.79%
H: 0.0%
C: 0.0%
ALXO M | $15.5 8.92% 8.19% 440K
|
Commercial Services
|
| O: 0.0%
H: 4.13%
C: 3.97%
aspen-06 treatment phase 2 phase 2/3 collaboration cancer initiated
ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022
Published: 2022-01-10 (Crawled : 12:00) - biospace.com/
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: -0.5%
H: 0.0%
C: 0.0%
ALXO M | $15.5 8.92% 8.19% 440K
|
Commercial Services
|
| O: -0.46%
H: 2.63%
C: 1.7%
milestone
ALX Oncology to Collaborate with Lilly to Evaluate ALX148 Plus CYRAMZA® (Ramucirumab), Trastuzumab, and Paclitaxel in Patients with Gastric or Gastroesophageal Junction Cancer
Published: 2021-06-10 (Crawled : 12:00) - biospace.com/
LLY | News | $745.69 1.96% 0.04% 4K
|
Health Technology
|
| O: 0.43%
H: 3.91%
C: 2.89%
ALXO M | $15.5 8.92% 8.19% 440K
|
Commercial Services
|
| O: -0.43%
H: 3.82%
C: 2.26%
cancer agx148
Gainers vs Losers
| 76% | 24% |
Top 10 Gainers
AGBA | $2.97 137.6% 54.87% 66M
|
Finance
HKIT | $1.33 30.39% 27.14% 39K
|
Technology Services
VRT 4 | $79.17 4.08% 19.36% 6.6M
|
Electronic Technology
PEGY | $0.0566 23.58% 15.65% 11M
|
Manufacturing
FOA 4 | $0.5144 -8.16% 15.43% 20
|
Finance and Insurance
BOF | $1.17 6.36% 14.73% 15K
|
LUCY | $0.2545 9.93% 13.94% 66K
|
n/a
PEB 4 | $15.45 2.45% 10.46% 130
|
Finance
MARA | $19.44 10.77% 10.28% 630K
|
Commercial Services
TSLA | News | $144.68 1.85% 9.01% 93M
|
Consumer Durables
Your saved searches
Save your searches and get alerts when important news are released.